Events

Speaker: Huseyin Naci (MHS, PhD), London School of Economics and Political Science
Description: The FDA’s accelerated approval pathway allows cancer drugs to reach patients sooner, often based on early trial results rather than proven survival benefit. In this webinar, Dr. Huseyin Naci will discuss findings from a recent BMJ Medicine study examining survival gains and Medicare spending associated with these approvals. Join us to explore what faster approval means for patients, evidence standards, and healthcare costs.

REGISTER TODAY!